Lataa...
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
OBJECTIVES: Pseudo-progression is a rare but worrying situation for both clinicians and patients during immunotherapy. Dedicated ir-RECIST criteria have been established to improve this situation. However, this can be sometimes considered inadequate and patients experiencing true progression may the...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5514971/ https://ncbi.nlm.nih.gov/pubmed/28445137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16935 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|